INmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private Placement
INmune Bio priced a registered direct offering of 3,000,000 shares with a single healthcare-focused institutional investor, with a concurrent private placement of warrants on another 3,000,000 shares. Gross proceeds are expected to be approximately $4.50 million before fees, with net proceeds earmarked for working capital and general corporate purposes. The warrants carry a $1.65 exercise price and are exercisable six months after issuance, expiring 5.5 years out. The deal closes on or about October 29, 2026, with A.G.P./Alliance Global Partners acting as sole placement agent.
Key figures
- Deal Value Usd
- 4500000
- Shares Offered
- 3000000
- Warrant term
- 5.5 years, exercisable six months post-issuance
- Warrant shares
- 3000000
- Warrant exercise price
- 1.65
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.